Abstract
Importance COVID-19 vaccine hesitancy has become a leading barrier to increasing the US vaccination rate.
Objective To evaluate time trends in COVID-19 vaccine intent during the US vaccine rollout, and identify key factors related to and self-reported reasons for COVID-19 vaccine hesitancy in May 2021.
Design, participants and setting A COVID-19 survey was offered to US adult Facebook users in several languages yielding 5,088,772 qualifying responses from January 6 to May 31, 2021. Data was aggregated by month. Survey weights matched the sample to the age, gender, and state profile of the US population.
Exposure Demographics, geographic factors, political/COVID-19 environment, health status, beliefs, and behaviors.
Main outcome measures “If a vaccine to prevent COVID-19 were offered to you today, would you choose to get vaccinated.” Hesitant was defined as responding probably or definitely would not choose to get vaccinated (versus probably or definitely would, or already vaccinated).
Results COVID-19 vaccine hesitancy decreased by one-third from 25.4% (95%CI, 25.3, 25.5) in January to 16.6% (95% CI, 16.4, 16.7) in May, with relatively large decreases among participants with Black, Pacific Islander or Hispanic race/ethnicity and ≤high school education. Independent risk factors for vaccine hesitancy in May (N=525,644) included younger age, non-Asian race, < 4 year college degree, living in a more rural county, living in a county with higher Trump vote share in the 2020 election, lack of worry about COVID-19, working outside the home, never intentionally avoiding contact with others, and no past-year flu vaccine. Differences in hesitancy by race/ethnicity varied by age (e.g., Black adults more hesitant than White adults <35 years old, but less hesitant among adults ≥45 years old). Differences in hesitancy by age varied by race/ethnicity. Almost half of vaccine hesitant respondents reported fear of side effects (49.2% [95%CI, 48.7, 49.7]) and not trusting the COVID-19 vaccine (48.4% [95%CI, 48.0, 48.9]); over one-third reported not trusting the government, not needing the vaccine, and waiting to see if safe. Reasons differed by degree of vaccine intent and by race/ethnicity.
Conclusion COVID-19 vaccine hesitancy varied by demographics, geography, beliefs, and behaviors, indicating a need for a range of messaging and policy options to target high-hesitancy groups.
Competing Interest Statement
Drs. King, Mejia and Mr. Rubenstein have no conflict of interest to report. Dr. Reinhart received salary support from an unrestricted gift from Facebook described in the funding section of the paper. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Funding Statement
This material is based upon work supported by Facebook (unrestricted gift) and a cooperative agreement from the Centers for Disease Control and Prevention (U01IP001121). Any opinions, findings and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of Facebook or the Centers for Disease Control and Prevention. Facebook was involved in the design and conduct of the study. The CDC provided funding only. Neither Facebook nor the Centers for Disease Control and Prevention had a role in the collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Carnegie Mellon University (CMU) Institutional Review Board approved the survey protocol and instrument.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Revisions from the first version: a new exclusion criteria, applicable to <1% of survey responses, was applied to the analysis sample. Specifically, participants who selected "prefer to self-describe" for gender were excluded because the majority of fill-in responses for self-described gender were discriminatory statements, and that as a group, those who selected self-described gender had a high frequency of uncommon responses (e.g., Hispanic ethnicity [41.4%], the oldest age group [23.2% ≥75 years] and highest education level [28.1% Doctorate]), suggesting the survey was not completed in good faith. A sensitivity analysis including these participants is provided in supplemental material. Revisions from the second version: Minor edits were made throughout to address reviewers' questions and requests.
Data Availability
To protect the confidentiality of survey respondents, access to survey microdata is restricted. Access is available to any academic or nonprofit researchers under a data use agreement. Information on how to request access can be found at https://cmu-delphi.github.io/delphi-epidata/symptom-survey/. Requests are reviewed by the Carnegie Mellon University Office of Sponsored Programs and Facebook Data for Good.
https://cmu-delphi.github.io/delphi-epidata/symptom-survey/coding.html
